Global generic drug and specialty pharmaceuticals maker Mylan has turned to a trio of firms for counsel on its $1.6 billion cash acquisition of Indian generic injectable drug manufacturer Agila Specialties from parent Strides Arcolab.
Mylan is currently the world’s fourth-largest producer of prescription generic drugs. The suburban Pittsburgh-based company states in a press release announcing the deal that purchasing Agila will help it increase its offerings of injectable drugs and expand into emerging markets such as Brazil and India.
